Cancer Screening Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The cancer screening market was valued at USD 26.58 Billion in 2025 and is expected to grow at a CAGR of 11.50%, reaching USD 78.94 Billion by 2035. The market growth is driven by increasing awareness of early detection programs and technological advancements in diagnostic screening.

Cancer Screening Market Overview

Cancer screening plays a crucial role in early disease detection, enabling timely treatment and improving survival rates. The rising prevalence of various cancers, including breast, cervical, and lung cancer, has intensified the demand for effective screening methods. Advancements in AI-powered diagnostics, liquid biopsies, and imaging technologies are enhancing detection accuracy and accessibility. Additionally, government initiatives promoting awareness and preventive healthcare are further driving adoption. As early diagnosis remains a priority in oncology care, the market is poised for sustained growth, shaping the future of healthcare by enabling improved patient outcomes.

Cancer Screening Market Growth Drivers

Rising Prevalence of Cancer

The global rise in various cancer types, such as cervical, breast, and colorectal cancer, is amplifying the need for early detection to initiate timely treatment and improve survival rates. Regular screening is becoming essential to identify cancers at an early stage, reducing mortality and enhancing patient outcomes. According to the American Cancer Society, in 2025, approximately 13,360 new cases of invasive cervical cancer are expected to be diagnosed in the United States, with about 4,320 women predicted to die from the disease. This growing burden is driving the demand for advanced screening, and diagnostics, boosting the market for innovative technologies and awareness campaigns to improve early detection and patient outcomes.

Technological Advancements to Drive Cancer Screening Market Value

Innovations in diagnostic technologies, including such as liquid-based cytology, advanced imaging techniques, and AI-powered tools, are revolutionizing cancer screening. These advancements offer faster results, improved precision, and enhanced patient outcomes, addressing critical needs in managing various cancer types. The integration of digital health platforms further drives efficiency in screening programs, making them more efficient and accessible. With increasing awareness and adoption of these cutting-edge solutions, the market is poised for significant growth.

Cancer Screening Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rise in Strategic Mergers and Acquisitions to Affect the Market Landscape Significantly

Prominent players in the market are stepping forward to enhance their cancer screening portfolio propelled by the surge in the demand for advanced screening technologies. For instance, in May 2024, Quest Diagnostics announced the acquisition of PathAI Diagnostics to advance AI and digital pathology in cancer diagnosis. The transaction included PathAI's digitized laboratory in Memphis, which became Quest's center for AI and digital R&D. Quest also licensed PathAI's AISight™ digital pathology system to enhance its pathology services across the United States. This collaboration aimed to improve diagnostic accuracy, speed, and accessibility, marks a significant milestone in integrating AI and digital solutions into oncology care and pathology services.

Increased Investments to Elevate the Cancer Screening Market Value

Key players are actively investing in cancer screening technologies, enabling advancements in early detection methods and improving diagnostic accuracy. These funds are supporting innovative research and expanding the development of non-invasive screening tools like blood-based tests. By addressing unmet medical needs, such investments are enhancing accessibility to cancer screening solutions. For instance, in February 2024, Freenome announced that it had raised USD 254 million in funding to advance its multi-omics platform for early cancer detection. The financing aimed to support clinical programs and expand platform capabilities for single-cancer and multi-cancer blood tests. Freenome highlighted its ongoing registrational studies, including PREEMPT CRC for colorectal cancer and PROACT LUNG for lung cancer. This funding positioned Freenome to innovate cancer screening, offering accessible, non-invasive blood-based tests to improve early diagnosis and patient outcomes globally.

Emphasis on Early Detection to Enhance Cancer Screening Market Demand

Leading healthcare companies are actively investing in innovative solutions to enhance early cancer detection and improve patient outcomes. For instance, in June 2024, DELFI Diagnostics announced an equity investment from Merck Global Health Innovation Fund to accelerate its AI-powered fragmentomics platform. This technology leverages whole-genome sequencing to detect cancer through cell-free DNA patterns, enhancing early-stage cancer screening accessibility and accuracy. DELFI’s FirstLook Lung test demonstrated 80% sensitivity for detecting early-stage lung cancer, with a 99.8% negative predictive value. The collaboration aims to address gaps in cancer detection and expand lung cancer screening access globally.

Surge in Regulatory Approvals to Augment the Cancer Screening Market Growth

Healthcare authorities are increasingly approving innovative screening solutions, ensuring patients have better access to life-saving cancer detection methods. For instance, in November 2023, Abbott received FDA approval for its molecular human papillomavirus (HPV) screening solution, Alinity m HR HPV assay. This innovative test provided genotype determination for 14 high-risk HPV types associated with cancer, enabling primary cervical cancer screening and co-testing. The test was designed to support patient care by delivering detailed risk assessments and helping physicians tailor follow-up plans. Abbott’s Alinity m platform further streamlined HPV testing with advanced molecular technology, showcasing the company’s commitment to improving diagnostic accuracy and patient outcomes. This regulatory momentum is continuously driving advancements in cancer diagnostics, ensuring timely and accurate screenings are becoming more accessible worldwide.

Cancer Screening Market Segmentation

Cancer Screening Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:

Market Breakup by Product

• Instruments
• Pathology-based Instruments Slide Staining Systems Tissue Processing Systems Cell Processors PCR Instruments NGS Instruments Microarrays Other Pathology-based Instruments
• Imaging Instruments CT Systems Ultrasound Systems MRI Systems Mammography Systems Nuclear Imaging Systems Others
• Biopsy Instruments
• Consumables
• Antibodies
• Kits and reagents
• Probes
• Others
• Services

Market Breakup by Application

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Cervical Cancer
• Others

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Diagnostic Labs
• Cancer Institutes
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Cancer Screening Market Share

Market Segmentation by Application is Projected to Hold a Substantial Market Share

Based on application, the market is divided into breast cancer, colorectal cancer, lung cancer, prostate cancer, cervical cancer, and others. Among these, breast cancer is expected to lead the market due to its high prevalence. As per the American Cancer Society, in 2024, an estimated 310,720 women were diagnosed with breast cancer in the United States, further reinforcing the importance of early screening. Increased awareness from campaigns and strong guidelines recommending regular screenings are further boosting demand.

Cancer Screening Market Segmentation by End User to Witness Significant Growth

Based on the end user, the market is segmented into hospitals, specialty clinics, diagnostic labs, cancer institutes, and others. Among these, hospitals are expected to lead the market share due to their comprehensive resources, access to advanced technologies, and ability to offer a wide range of diagnostic and treatment services all in one place. Being the primary healthcare providers, hospitals are often the first point of contact for patients seeking cancer screenings, and they are equipped with the necessary facilities and specialists, including oncologists and radiologists. As the demand for cancer screenings continues to grow, driven by rising awareness, early detection initiatives, and increasing cancer incidence rates, hospitals are positioning themselves to expand their screening programs. Further, the investments in advanced screening technologies and focus on improving patient access in hospitals will likely drive the market value of this segment in the forecast period.

Cancer Screening Market Analysis by Region

Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among these, North America is expected to dominate the market due to several factors, including a high prevalence rate of cancer, advanced healthcare infrastructure, and strong government initiatives aimed at promoting early detection and screening. The region has one of the highest rates of cancer diagnosis, which drives demand for screening services. Additionally, the presence of numerous leading healthcare facilities and diagnostic laboratories, along with significant investments in research and development for innovative screening technologies, enhance access to and quality of cancer screening. Moreover, several organizations actively promote screening programs, further increasing participation rates. Overall, the focus on quality healthcare delivery, coupled with ongoing advancements, positions it as a significant driver of growth in the market during the forecast period.

Leading Players in the Cancer Screening Market

The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

DiaSorin S.p.A.

The company established in 2000 and headquartered in Saluggia, Italy, is a global leader in immunodiagnostics and molecular diagnostics. The company specializes in developing innovative solutions for infectious diseases, oncology, and genetic disorders. In cancer screening, DiaSorin offers the LIAISON® chemiluminescence immunoassay analyzers and Simplexa™ molecular diagnostic tests, enabling early detection and monitoring of cancer biomarkers. These products provide high sensitivity and specificity, supporting oncologists in making informed clinical decisions, improving patient outcomes, and advancing precision medicine.

Biodesix

Biodesix founded in 2005 and headquartered in Boulder, Colorado, focuses on lung cancer diagnostics through innovative blood-based tests. The company's Nodify XL2® and Nodify CDT® tests help assess the risk of malignancy in pulmonary nodules, enabling early cancer detection. Additionally, VeriStrat®, a proteomic test, provides prognostic insights for advanced non-small cell lung cancer (NSCLC). Biodesix leverages machine learning and genomics to enhance cancer screening accuracy, supporting precision medicine and improving treatment pathways for lung cancer patients.

MedGenome Labs Ltd

MedGenome Labs, established in 2013 and headquartered in Foster City, California, is a leading genomics and molecular diagnostics company specializing in oncology. The company offers OncoTrack, a comprehensive cancer gene panel that identifies somatic mutations for early cancer detection and treatment selection. MedGenome utilizes next-generation sequencing (NGS) and liquid biopsy techniques to analyze tumor genetics, enabling personalized therapy recommendations. Their innovative approach enhances cancer screening by improving diagnostic accuracy, supporting oncologists with actionable insights, and advancing precision oncology in global healthcare.

20/20 GeneSystems

The company established in 2000 and headquartered in Rockville, Maryland, develops AI-driven diagnostic solutions for early cancer detection. Their flagship product, OneTest, is a multi-cancer screening blood test that detects biomarkers associated with lung, liver, pancreatic, and other cancers. OneTest combines machine learning with traditional tumor markers to improve early diagnosis and risk assessment. By offering affordable and accessible screening, 20/20 GeneSystems aims to enhance early cancer detection, reduce mortality rates, and support preventive healthcare initiatives worldwide.

Other key players in the market include Abbott, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., GE Healthcare, Koninklijke Philips N.V., and QIAGEN.

Key Questions Answered in the Cancer Screening Market

• What is the global cancer screening market forecast outlook for 2026-2035?
• What are the regional markets covered in The report?
• What is the market segmentation based on the product?
• What is the market breakup based on the application?
• What is the market segmentation based on the end user?
• What are the major factors aiding the cancer screening market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major cancer screening market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the cancer screening market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

More Insights On

Lung Cancer Screening Market Liver Cancer Screening Market